Health Economics – Clinical Value of Diagnostics https://clinicalvalue.com Fri, 25 Apr 2025 09:23:08 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.2 https://i0.wp.com/clinicalvalue.com/wp-content/uploads/2023/01/apple-touch-icon.png?fit=32%2C32&ssl=1 Health Economics – Clinical Value of Diagnostics https://clinicalvalue.com 32 32 225041835 Cost-Utility of Novel Biomarker-Based Strategies for Hepatocellular Carcinoma (HCC) Surveillance in Thailand https://clinicalvalue.com/cost-utility-of-novel-biomarker-based-strategies-for-hepatocellular-carcinoma-hcc-surveillance-in-thailand/ https://clinicalvalue.com/cost-utility-of-novel-biomarker-based-strategies-for-hepatocellular-carcinoma-hcc-surveillance-in-thailand/#comments Thu, 27 Jun 2024 06:56:32 +0000 https://clinicalvalue.com/?p=8722 ...

The post Cost-Utility of Novel Biomarker-Based Strategies for Hepatocellular Carcinoma (HCC) Surveillance in Thailand appeared first on Clinical Value of Diagnostics.

]]>

The post Cost-Utility of Novel Biomarker-Based Strategies for Hepatocellular Carcinoma (HCC) Surveillance in Thailand appeared first on Clinical Value of Diagnostics.

]]> https://clinicalvalue.com/cost-utility-of-novel-biomarker-based-strategies-for-hepatocellular-carcinoma-hcc-surveillance-in-thailand/feed/ 1 8722 Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost–effectiveness analysis https://clinicalvalue.com/gaad-hecon-china-early-liver-cancer/ Tue, 05 Mar 2024 05:03:08 +0000 https://clinicalvalue.com/?p=8092 ...

The post Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost–effectiveness analysis appeared first on Clinical Value of Diagnostics.

]]>

Quick Summary

The recently published Chinese standards for the diagnosis and treatment of primary liver cancer [1] mention various screening strategies, including abdominal ultrasonography (US), serological tests such as alpha-fetoprotein (AFP) and protein induced by vitamin K absence/antagonist-II (PIVKA-II).

However, combined screening strategies may be associated with increased costs. The Chinese guidelines [2] highlight that there is a lack of health economic evaluations and evidence on the cost–effectiveness of different liver cancer screening strategies.

This study aims to compare the cost-effectiveness of seven screening strategies:

  1. US
  2. AFP
  3. PIVKA-II
  4. AFP+US
  5. AFP+PIVKA-II
  6. GAAD
  7. GAAD+US

This was done by developing a health economic model from the Chinese healthcare system perspective to identify the most cost-effective strategy for early detection of liver cancer in patients with chronic hepatitis B in China.

Access the full publication

The post Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost–effectiveness analysis appeared first on Clinical Value of Diagnostics.

]]> 8092 Surveillance of Hepatocellular Cancer Among Hepatitis B and Cirrhosis Patients Using Protein Induced by Vitamin K Absence-II (PIVKA-II): A Cost-Utility Analysis for Hong Kong as an Example of Endemic Regions https://clinicalvalue.com/surveillance-of-hepatocellular-cancer-among-hepatitis-b-and-cirrhosis-patients-using-protein-induced-by-vitamin-k-absence-ii-pivka-ii-a-cost-utility-analysis-for-hong-kong-as-an-example-of-endemic/ Tue, 14 Mar 2023 09:23:53 +0000 https://clinicalvalue.com/?p=6514 This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic hepatitis B patients in China.

Leung MK, Ko M, Chen J, Garay OU, Leung B, Chow C, Li E, Wu JTK, Yuen MF, Zheng Q...

The post Surveillance of Hepatocellular Cancer Among Hepatitis B and Cirrhosis Patients Using Protein Induced by Vitamin K Absence-II (PIVKA-II): A Cost-Utility Analysis for Hong Kong as an Example of Endemic Regions appeared first on Clinical Value of Diagnostics.

]]>

The post Surveillance of Hepatocellular Cancer Among Hepatitis B and Cirrhosis Patients Using Protein Induced by Vitamin K Absence-II (PIVKA-II): A Cost-Utility Analysis for Hong Kong as an Example of Endemic Regions appeared first on Clinical Value of Diagnostics.

]]> 6514 Cost-effectiveness Analysis of GAAD algorithm on Hepatocellular Carcinoma Screening in Patients with Chronic Hepatitis B in China https://clinicalvalue.com/cost-effectiveness-analysis-of-gaad-algorithm-on-hepatocellular-carcinoma-screening-in-patients-with-chronic-hepatitis-b-in-china/ Tue, 14 Mar 2023 09:15:08 +0000 https://clinicalvalue.com/?p=6487 This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic hepatitis B patients in China.

Chen W, Nan YM, Garay U, Lu X, Zhang Y, Xie L, Niu Z...

The post Cost-effectiveness Analysis of GAAD algorithm on Hepatocellular Carcinoma Screening in Patients with Chronic Hepatitis B in China appeared first on Clinical Value of Diagnostics.

]]>

The post Cost-effectiveness Analysis of GAAD algorithm on Hepatocellular Carcinoma Screening in Patients with Chronic Hepatitis B in China appeared first on Clinical Value of Diagnostics.

]]> 6487